nit2 Antibody

What is NIT2 and what are its primary biological functions?

NIT2 (Nitrilase family member 2) belongs to the nitrilase superfamily of enzymes that cleave carbon-nitrogen bonds. It functions primarily as an omega-amidase that catalyzes the hydrolysis of alpha-ketoglutaramate to form alpha-ketoglutarate and ammonia . This reaction is functionally coupled with a subset of transaminases that reaminate the keto acid analogs of essential amino acids, particularly methionine and phenylalanine .

The biological significance of NIT2 extends beyond simple metabolic functions:

• It plays a crucial role in nitrogen and sulfur metabolism by removing potentially toxic intermediates (α-ketoglutaramate and α-ketosuccinamate)

• It converts these toxic intermediates into biologically useful compounds (α-ketoglutarate and oxaloacetate, respectively)

• It has been implicated in tumor suppression mechanisms, arresting cells in the G2 phase without inducing apoptosis

• Recent research suggests it may influence 5-FU chemoresistance in gastric cancer through mechanisms independent of its nitrilase enzymatic function

What are the recommended applications and dilutions for NIT2 antibody?

The optimal applications and dilutions for NIT2 antibody vary based on the specific antibody clone and experimental design. Based on the validated data:

It's important to note that optimal dilutions are sample-dependent, and researchers should perform titration experiments with their specific samples to determine the optimal conditions . For newly tested sample types, a preliminary dilution series is recommended to establish signal-to-noise ratios.

How should I select the appropriate NIT2 antibody for my experiment?

When selecting a NIT2 antibody, consider these critical factors:

• Validated reactivity: Ensure the antibody has been validated for your species of interest. Commercial NIT2 antibodies have confirmed reactivity with human, mouse, rat, and pig samples .

• Application compatibility: Verify the antibody has been validated for your specific application. Some NIT2 antibodies are validated for multiple applications (WB, IHC, IF/ICC), while others may be optimized for specific techniques .

• Antibody type: Choose between:

  • Monoclonal antibodies (e.g., Mouse IgG2b) for high specificity

  • Polyclonal antibodies for broader epitope recognition and potentially stronger signals

• Epitope location: Consider antibodies targeting different regions of NIT2. Some target the C-terminus (aa 250 to C-terminus) , which may be preferable depending on your research questions.

• Storage conditions: Most NIT2 antibodies should be stored at -20°C in buffers containing stabilizers like glycerol. Aliquoting may be unnecessary for -20°C storage in some formulations .

How is NIT2 implicated in cancer biology and chemotherapy resistance?

NIT2 has emerged as a significant player in cancer biology through multiple mechanisms:

• Tumor suppressor properties: Evidence suggests NIT2 functions as a tumor suppressor by arresting cells in the G2 phase without inducing apoptosis . Genotype analysis in four types of human primary tumors showed 12.5–38.5% allelic imbalance surrounding the NIT2 genomic locus .

• 5-FU chemoresistance: Recent research revealed that low expression of NIT2 promotes 5-FU chemoresistance in gastric cancer through a mechanism independent of its nitrilase enzymatic function. This occurs through increasing oxidative phosphorylation .

• Therapeutic implications: Using metformin (an oxidative phosphorylation inhibitor) increased 5-FU efficacy in patient-derived xenografts with low NIT2 expression, suggesting a potential strategy for overcoming chemoresistance .

• Cell signaling modulation: NIT2 appears to affect growth suppression through a dual mechanism involving up-regulation of the 14-3-3σ gene and down-regulation of the 14-3-3β gene . Since upregulation of 14-3-3σ triggers cell cycle arrest in G2 and inhibits Akt-activated cell growth, while 14-3-3β reduction results in tumor suppression, these pathways may explain part of NIT2's anti-tumor effects.

• Expression in cancer models: In human MCF7 breast cancer cells transfected with ErbB2 (HER2), a 70% reduction in NIT2 protein was observed compared to untransfected cells . This finding is significant as ErbB2 overexpression is associated with aggressive cell growth in breast cancers.

When designing experiments to investigate NIT2's role in cancer, researchers should consider both enzymatic and non-enzymatic functions, and incorporate oxidative phosphorylation analysis into their methodologies.

What is the role of NIT2 in amino acid metabolism and how can it be studied?

NIT2's role in amino acid metabolism is complex and centers on its omega-amidase activity:

• Essential amino acid salvage: NIT2 functions in conjunction with glutamine transaminases to salvage α-keto acids generated through non-specific transamination reactions, particularly those of essential amino acids .

• Methionine salvage: NIT2 is critical in the methionine salvage pathway, where glutamine transaminases play an important role in transaminating α-keto-γ-methiolbutyrate .

• Toxicity prevention: NIT2 removes potentially toxic intermediates:

  • α-ketoglutaramate (potentially neurotoxic)

  • α-ketosuccinamate (unstable and convertible to toxic heteroaromatic compounds)

To study NIT2's metabolic functions, researchers can employ these methodologies:

• Enzyme activity assays: Measure ω-amidase activity using α-ketoglutaramate and α-ketosuccinamate as substrates, monitoring the production of α-ketoglutarate and oxaloacetate.

• Metabolic flux analysis: Use isotope-labeled amino acids (particularly glutamine, asparagine, methionine) to track metabolic pathways and identify NIT2's contribution.

• Protein-protein interaction studies: Investigate NIT2's interactions with transaminases and other metabolic enzymes using co-immunoprecipitation with NIT2 antibodies.

• Genetic manipulation: Use NIT2 knockdown/knockout models to assess the impact on amino acid metabolism, particularly under conditions of metabolic stress.

How can I distinguish between enzymatic and non-enzymatic functions of NIT2?

Distinguishing between NIT2's enzymatic and non-enzymatic functions requires careful experimental design:

• Site-directed mutagenesis: Generate catalytically inactive NIT2 mutants by mutating key residues in the active site while preserving protein structure. Compare the phenotypic effects of wild-type vs. catalytically inactive NIT2 to separate enzymatic from non-enzymatic functions.

• Substrate competition assays: Use competitive inhibitors of NIT2's omega-amidase activity without affecting protein-protein interactions to isolate enzymatic contributions.

• Domain-specific antibodies: Employ antibodies targeting different domains of NIT2 to potentially block specific functions while preserving others.

• Enzymatic activity correlation: In cancer models like those studying 5-FU resistance, measure both NIT2 expression and omega-amidase activity to determine if resistance correlates with enzyme activity or merely protein expression .

• Subcellular localization: Analyze the subcellular distribution of NIT2 using immunofluorescence with NIT2 antibodies, as certain functions may correlate with specific localizations.

This approach has proven valuable in research showing that NIT2's role in 5-FU resistance appears independent of its enzymatic function, instead involving oxidative phosphorylation regulation .

What are the optimal conditions for using NIT2 antibodies in Western blot analysis?

For optimal Western blot detection of NIT2:

• Sample preparation:

  • Lyse cells in phosphate buffer containing non-ionic detergents (e.g., Nonidet-P40), 1mM EDTA, and protease inhibitors

  • Include reducing agents like DTT (1mM) to prevent air oxidation of NIT2

• Gel electrophoresis:

  • Use appropriate percentage gels for detecting the 31 kDa NIT2 protein

  • Load positive control samples from validated cell lines (HEK-293, HeLa, HepG2, or Jurkat cells)

• Antibody conditions:

  • Primary antibody: Use 1:5000 to 1:50000 dilution of NIT2 antibody in blocking buffer

  • Secondary antibody: Select appropriate HRP-conjugated secondary matching the host species of your primary antibody

• Detection considerations:

  • NIT2 typically appears as a 31 kDa band

  • Be aware that NIT2 naturally exists as a homodimer (~62 kDa) that may be detected under non-reducing conditions

  • Some cancer cells may show phosphorylated forms of NIT2, resulting in slightly higher molecular weight bands

• Optimization tips:

  • Perform a titration of antibody concentrations for each new sample type

  • Include positive and negative control samples

  • If detecting endogenous NIT2, be aware that expression levels vary significantly between tissues and cell lines

What controls should be used when validating NIT2 antibody specificity?

Rigorous validation of NIT2 antibody specificity requires multiple controls:

• Positive controls:

  • Cell/tissue types with confirmed NIT2 expression: HEK-293, HeLa, HepG2, Jurkat cells, pig/mouse liver tissue

  • Recombinant NIT2 protein or NIT2-overexpressing cells

• Negative controls:

  • NIT2 knockout or knockdown cells/tissues

  • Isotype control antibodies to rule out non-specific binding

  • Primary antibody omission to detect secondary antibody artifacts

• Specificity controls:

  • Peptide competition assay: Pre-incubate NIT2 antibody with the immunizing peptide before application

  • Cross-reactivity testing with related proteins (especially other nitrilase family members)

• Application-specific controls:

  • For IHC: Include both positive and negative tissue sections in each staining run

  • For IF/ICC: Include counterstains to verify subcellular localization patterns

• Multiple antibody validation:

  • Compare results using antibodies raised against different epitopes of NIT2

  • Compare monoclonal vs. polyclonal antibody results

A comprehensive validation approach increases confidence in experimental results and helps troubleshoot inconsistencies between different detection methods.

How should samples be prepared for optimal NIT2 detection in immunohistochemistry?

For optimal immunohistochemical detection of NIT2:

• Fixation protocol:

  • Formalin fixation followed by paraffin embedding is suitable for NIT2 detection

  • Standardize fixation time to prevent over-fixation, which may mask epitopes

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (HIER) is typically more effective than enzymatic methods

• Blocking parameters:

  • Block endogenous peroxidase activity with hydrogen peroxide solution

  • Use species-appropriate serum or protein-based blocking solution to reduce background

• Antibody application:

  • Recommended dilution range: 1:200-1:800

  • Optimize incubation time and temperature (typically overnight at 4°C or 1-2 hours at room temperature)

  • Consider using antibody diluent with background-reducing components

• Detection system:

  • Use polymer-based detection systems for enhanced sensitivity

  • For dual staining experiments, use detection systems with distinct chromogens

• Counterstaining:

  • Hematoxylin counterstaining provides good nuclear contrast

  • Adjust counterstaining time to achieve optimal visualization of NIT2 staining pattern

• Positive control tissue:

  • Human kidney tissue has been validated for NIT2 detection

  • Include positive control sections with each staining batch

What approaches can resolve weak or non-specific NIT2 antibody signals?

When troubleshooting NIT2 antibody performance:

• For weak or absent signals:

  • Increase antibody concentration (while monitoring background)

  • Extend primary antibody incubation time (e.g., overnight at 4°C)

  • Optimize antigen retrieval: Try both TE buffer pH 9.0 and citrate buffer pH 6.0

  • Use more sensitive detection systems (polymer-based or tyramide signal amplification)

  • Check sample integrity: Verify protein expression using alternative methods

  • Avoid repeated freeze-thaw cycles of antibody, which may reduce activity

• For high background or non-specific binding:

  • Dilute primary antibody further (test a dilution series)

  • Extend blocking time or use alternative blocking reagents

  • Increase washing duration and frequency

  • Reduce secondary antibody concentration

  • For IHC: Pre-block endogenous biotin if using avidin-biotin systems

  • For IF: Include an autofluorescence quenching step

• For inconsistent results:

  • Standardize sample preparation protocols

  • Use fresh reagents and antibody aliquots

  • Verify antibody specificity using knockout/knockdown controls

  • Consider lot-to-lot variability in antibodies

  • Check for potential interfering substances in your samples

• Application-specific approaches:

  • For Western blot: Adjust transfer conditions for 31 kDa proteins; include reducing agents

  • For IHC: Test multiple fixation protocols and antigen retrieval methods

  • For IF/ICC: Optimize permeabilization conditions for accessing intracellular epitopes

By systematically addressing these factors, researchers can significantly improve NIT2 detection outcomes across various experimental platforms.

How is NIT2 being investigated in relation to novel cancer therapeutic approaches?

NIT2's emerging role in cancer biology opens several promising research avenues:

• Chemoresistance mechanisms: Recent research has revealed that low NIT2 expression promotes 5-FU resistance in gastric cancer through increased oxidative phosphorylation . This finding suggests that:

  • NIT2 expression levels could serve as a biomarker for predicting 5-FU treatment response

  • Combining oxidative phosphorylation inhibitors (like metformin) with 5-FU may overcome resistance in tumors with low NIT2 expression

• Cell cycle regulation: NIT2's ability to arrest cells in G2 phase without inducing apoptosis presents opportunities for:

  • Developing cell cycle-specific cancer therapeutics

  • Understanding mechanisms of cell cycle checkpoint control

  • Investigating combination therapies targeting specific cycle phases

• Protein interaction pathways: NIT2 affects expression of 14-3-3σ and 14-3-3β genes , suggesting:

  • Potential for targeting downstream effectors in the NIT2 pathway

  • Opportunities to modulate 14-3-3 proteins as therapeutic targets

  • Investigating interactions between NIT2 and other tumor suppressors

• Metabolic reprogramming: As an omega-amidase involved in nitrogen metabolism, NIT2 may influence cancer metabolic reprogramming:

  • Research could explore connections between NIT2 activity and glutamine metabolism in tumors

  • NIT2's role in removing toxic metabolites may affect tumor microenvironment

Researchers investigating these areas should employ comprehensive approaches including NIT2 antibody-based detection methods, metabolic analysis, and functional studies with genetic manipulation of NIT2 expression.

What methodologies are recommended for studying NIT2 protein interactions?

To effectively study NIT2 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use anti-NIT2 antibodies for pull-down experiments

  • Since NIT2 naturally forms homodimers (~62 kDa) , include conditions that preserve or disrupt dimerization

  • Consider crosslinking approaches to capture transient interactions

  • Validate interactions with reciprocal Co-IP using antibodies against interaction partners

• Proximity labeling technologies:

  • BioID or APEX2 fusion proteins with NIT2 can identify proximal proteins in living cells

  • These methods are particularly valuable for identifying transient or weak interactions in native cellular contexts

• Two-hybrid systems:

  • Yeast or mammalian two-hybrid screening can identify potential binding partners

  • Verify interactions using alternative methods as two-hybrid systems may yield false positives

• Bimolecular fluorescence complementation (BiFC):

  • Enables visualization of protein interactions in living cells

  • Particularly useful for studying NIT2 interactions in different subcellular compartments

• Protein microarrays:

  • Screen for interactions with purified recombinant NIT2 protein

  • Can identify novel interaction partners from large protein libraries

• Structural studies:

  • X-ray crystallography of NIT2 with interaction partners

  • Mouse NIT2 has been shown to crystallize as a dimer , providing structural insights

• Functional validation:

  • After identifying potential interaction partners, validate functional significance through genetic manipulation (knockout/knockdown)

  • Assess the impact of mutations at interaction interfaces

These methodologies, particularly when used in combination, provide comprehensive insights into NIT2's interactome and its functional significance in different cellular contexts.